ABSTRACT

Objective

To investigate whether miRNAs have a remarkable pooled diagnostic accuracy, sensitivity, and specificity as noninvasive biomarkers to distinguish endometriosis patients from non-endometriosis women.

Methods

A comprehensive literature search of PubMed, Embase, and ProQuest was performed through February 21, 2021 to find relevant studies. Two reviewers independently screened each article, and discrepancies were resolved by consensus. Deeks’ funnel plot asymmetry test was performed to assess the publication bias of included studies. The STATA software and RevMan 5.4 were used for data analysis and quality assessment, respectively.

Results

The overall quality of the studies was moderate to high. In total 87 datasets were assessed miRNAs’ performance which results in sensitivity: 0.82, specificity: 0.79, DOR: 18, NPV: 0.80, PPV: 0.78, PLR: 3.97, and NLR: 022. We conducted subgroup analyses, which showed panels of miRNAs (DOR: 54) and serum (DOR: 43) as a target tissue was more reliable to utilize as biomarkers. Deeks’ funnel plot showed that there is no publication bias (P-value = 0.25).

Conclusions

Panels of miRNAs differentiate endometriosis patients from non-endometriosis women with high sensitivity and specificity; therefore, it has the potential to use as a noninvasive biomarker.

中文翻译：

---

microRNA作为子宫内膜异位症患者的新型诊断生物标志物：系统评价和荟萃分析

摘要

客观的

研究 miRNA 作为非侵入性生物标志物是否具有显着的综合诊断准确性、敏感性和特异性，以区分子宫内膜异位症患者和非子宫内膜异位症女性。

方法

在 2021 年 2 月 21 日之前对 PubMed、Embase 和 ProQuest 进行了全面的文献检索，以查找相关研究。每篇文章由两名审稿人独立筛选，分歧通过协商一致解决。进行 Deeks 漏斗图不对称检验以评估纳入研究的发表偏倚。STATA 软件和 RevMan 5.4 分别用于数据分析和质量评估。

结果

研究的总体质量中等至高。总共评估了 87 个数据集 miRNA 的性能，结果敏感性：0.82，特异性：0.79，DOR：18，NPV：0.80，PPV：0.78，PLR：3.97 和 NLR：022。我们进行了亚组分析，显示了miRNA (DOR: 54) 和血清 (DOR: 43) 作为靶组织更可靠地用作生物标志物。Deeks 漏斗图显示不存在发表偏倚（P值 = 0.25）。

结论

一组 miRNA 以高灵敏度和特异性区分子宫内膜异位症患者和非子宫内膜异位症女性；因此，它有可能用作非侵入性生物标志物。